What is Dexcom Stelo?
Dexcom Stelo is the first OTC continuous glucose monitor (CGM) for non-diabetic consumers, cleared via FDA De Novo pathway March 2024. Stelo carries Dexcom's medical-sensor heritage + a Vertex AI / Gemini generative AI insight layer that distinguishes it from Abbott Lingo's adaptive algorithmic AI substance. Pricing: ~$89 per 2-week sensor + biweekly subscription model. Per DEPLOY's biometric cluster framework, Stelo is the cohort's medical-sensor-with-AI-insight bridge cell anchor: passes biometric boundary test via genuine generative AI substance (not adaptive algorithmic) per Agent A Wave 2 + Wave 3 ingest.
First-of-kind OTC CGM De Novo (March 2024)
Dexcom Stelo is the first FDA-cleared over-the-counter continuous glucose monitor (CGM) for non-diabetic consumers in the United States. De Novo pathway clearance March 2024 established a new regulatory category for OTC consumer CGM. Cleared scope: OTC indication (no prescription required); non-diabetic indication (general-wellness glucose monitoring for non-diabetics); specifically NOT cleared for diabetes diagnosis or treatment decisions (those continue to require Dexcom G6 + G7 prescription-only medical-device CGM lines). Per DEPLOY's verified-vs-claimed framework, Stelo's De Novo establishes the verification anchor for the consumer glucose monitoring tier.
Genuine generative AI substance: Vertex AI / Gemini integration
Stelo's distinguishing characteristic in the biometric cohort is the AI-insight layer: Vertex AI / Gemini integration for insight generation based on glucose data patterns. Per Agent A Wave 3 ingest, the AI substance is genuine generative AI (LLM-based insight generation; pattern interpretation + contextual recommendations); structurally distinct from adaptive algorithmic AI substance in glucose-cell peers (Abbott Lingo per Agent A Wave 3 gradient documentation). Per DEPLOY's framework, the AI-substance distinction determines biometric cluster inclusion: Stelo passes the biometric-primary + AI-augmented boundary test via this generative substance.
Medical-sensor-with-AI-insight bridge cell + Dexcom medical-device heritage
Stelo extends Dexcom's medical-device CGM heritage (G6 + G7 generations for diabetic patients; prescription-only; medical-device tier) into the consumer-wellness market via OTC indication + AI-insight layer. The bridge cell role in DEPLOY's biometric cluster framework: medical-sensor sensor modality (continuous glucose monitoring) paired with consumer-wellness FDA posture (OTC general-wellness) + AI-insight differentiation (Vertex AI / Gemini). The bridge demonstrates how medical-device manufacturers can extend into biometric wearable cohort via specific OTC clearance pathways + AI-augmented insight delivery.
Consumable-sensor business model distinct in cohort
Stelo's consumable-sensor business model is structurally distinct from other biometric cohort hardware. Pricing: ~$89 per 2-week sensor + biweekly subscription enables continuous coverage. Contrast with cohort: most biometric wearables operate one-time hardware purchase + optional subscription (Fitbit + Withings + Pixel Watch); Whoop operates subscription-only with no separate hardware purchase; Oura operates purchase + required membership. Stelo's biweekly-sensor structure reflects the medical-sensor heritage (CGM sensors have finite operational lifetimes by design).
Cap-flag: marketing scope must not extend into diabetes management
Per cap-flag-as-trust-signal, Stelo's OTC clearance is specifically for general-wellness glucose monitoring for non-diabetics. The clearance scope does NOT cover diabetes diagnosis, diabetes treatment decisions, or insulin dosing guidance. Diabetic patients continue to require Dexcom G6 + G7 prescription-only CGM lines for medical-device tier glucose monitoring. Per DEPLOY's framework, marketing scope vs cleared scope must align; trade-press coverage that frames Stelo as a diabetes management tool operates outside cleared indication. The Whoop BPI case demonstrates the structural risk when marketing diverges from cleared scope.
Dexcom Stelo: glucose-biometric cell anchor + medical-sensor-with-AI-insight bridge
Dexcom Stelo is the first FDA-cleared over-the-counter continuous glucose monitor (CGM) for non-diabetic consumers in the United States. Cleared via FDA De Novo pathway March 2024, Stelo extends Dexcom's medical-device CGM heritage (G6 + G7 generations for diabetic patients) into the consumer-wellness market.
Per DEPLOY's biometric cluster framework, Stelo anchors the glucose-biometric cell + medical-sensor-with-AI-insight bridge cell. The boundary test for biometric cluster inclusion is: does the device pass biometric-primary + AI-augmented characterization? Per Agent A Wave 2 + Wave 3 foundational ingest, Stelo passes via genuine generative AI substance (Vertex AI / Gemini integration for insight generation), distinct from adaptive algorithmic AI substance in cohort peers (Abbott Lingo as the canonical counterpoint per Agent A Wave 3 gradient documentation).
FDA portfolio: OTC CGM De Novo March 2024
Stelo's clearance is the first-of-kind OTC CGM De Novo for non-diabetic consumers:
- OTC indication: cleared for purchase without prescription; consumers can buy Stelo directly through Dexcom + selected retailers.
- Non-diabetic indication: cleared for general-wellness glucose monitoring; specifically not cleared for diabetes diagnosis or treatment decisions (those continue to require Dexcom G6 + G7 medical-device CGM lines).
- De Novo pathway: novel device classification cleared, not 510(k) substantial-equivalence; FDA established new regulatory category for OTC consumer CGM.
Per DEPLOY's verified-vs-claimed framework, Stelo's OTC De Novo clearance is the verification anchor for the consumer glucose monitoring tier. The clearance scope is specific (general-wellness glucose monitoring for non-diabetics); marketing scope should not extend into diabetes management territory.
AI substance gradient: generative vs adaptive algorithmic
Stelo's distinguishing characteristic in the cohort is the AI-insight layer: Vertex AI / Gemini integration for insight generation based on glucose data patterns. Per Agent A Wave 3 ingest, the AI substance is genuine generative AI (LLM-based insight generation; pattern interpretation + contextual recommendations); structurally distinct from adaptive algorithmic AI in glucose-cell peers.
The cohort gradient (per Agent A Wave 3 documentation):
- Dexcom Stelo: generative AI substance (Vertex AI / Gemini); biometric cluster anchor via this substance distinction.
- Abbott Lingo: adaptive algorithmic AI substance (rule-based + pattern matching; not LLM-generative); per Agent A Wave 3, sits at AI-substance gradient below Stelo at the biometric boundary.
The distinction matters editorially because it determines biometric cluster inclusion. Stelo passes the boundary test; Lingo would sit at the AI-substance gradient that makes biometric cluster inclusion cap-flag tier. Per DEPLOY's framework, AI-substance gradient documentation honestly is the editorial discipline; biometric cohort inclusion requires verifiable AI-substance depth.
Product + business model
Pricing: ~$89 per 2-week sensor + biweekly subscription model. Stelo ships in 2-week sensor packs; biweekly subscription enables continuous coverage. The medical-sensor pricing structure contrasts with other biometric cohort hardware (one-time hardware purchase + optional subscription); Stelo's consumable-sensor business model is structurally distinct.
Distribution: Dexcom direct + selected retailers; OTC indication enables broader distribution than prescription-only Dexcom G6/G7 medical-device CGM lines.
Companion app: Stelo iOS + Android app surfaces glucose data + AI-insights; integrates with Vertex AI / Gemini for insight generation.
Cross-property surface state: Dexcom Stelo consumer /price page is not yet on the consumer surface as of mid-2026 (Agent B biometric continuation Wave 3 banked includes glucose-biometric pair). The Dexcom company entity + the Stelo registry model carry canonical institutional depth in the meantime.
Cohort positioning + cell-anchor framework
Per the biometric cluster framework, Stelo anchors:
- Glucose-biometric cell: distinct cell from cardiac-monitoring biometric cohort (Apple Watch + Pixel Watch + Withings + Garmin + Samsung); structurally different sensor modality (continuous glucose monitoring vs PPG/ECG-based cardiac signals).
- Medical-sensor-with-AI-insight bridge cell: extends Dexcom's medical-device heritage (G6/G7 prescription CGM) into consumer-wellness via OTC indication + genuine generative AI insight layer.
- First-of-kind OTC CGM: De Novo March 2024 established new regulatory category for consumer glucose monitoring.
- Generative AI substance anchor: Vertex AI / Gemini integration as cohort's anchor for genuine generative AI in biometric AI-insight layer (per Agent A Wave 3 gradient).
Contrast with cohort:
- Dexcom G6 + G7 (medical-device CGM): prescription-only for diabetic patients; medical-device tier (not biometric cluster).
- Abbott Lingo (glucose-cell peer): adaptive algorithmic AI substance; biometric cohort inclusion cap-flagged per Agent A Wave 3 gradient.
- Apple Watch + Pixel Watch + Withings + Garmin + Samsung Galaxy Watch + Fitbit: cardiac-monitoring biometric cohort; PPG/ECG-based sensors; structurally distinct cell from glucose monitoring.
- Oura + Whoop: ring + band biometric cohort; PPG-based sensors; general-wellness or lighter-cleared FDA posture.
For the canonical biometric cohort context, see the biometric cluster. For adjacent AI wearables cohort context, see what is an AI wearable. For the canonical category umbrella, see what is physical AI. For methodology canonical references applicable to Dexcom Stelo: verified-vs-claimed at within-entity granularity (within-Dexcom Stelo OTC vs G7 prescription product-family verification scope; CANONICAL OTC glucose with generative AI substance) + the 9-tier source-quality rubric (FDA OTC clearance primary-government-record source classification).
Sources: Source: DEPLOY registry + FDA De Novo + 510(k) databases + Agent A biometric Wave 2 + Wave 3 foundational. Sensor modality + AI substance + clearance pathway framework.
Frequently Asked Questions
What is Dexcom Stelo?
Dexcom Stelo is the first FDA-cleared over-the-counter continuous glucose monitor (CGM) for non-diabetic consumers in the United States. Cleared via FDA De Novo pathway March 2024. Stelo extends Dexcom's medical-device CGM heritage (G6 + G7 generations for diabetic patients) into the consumer-wellness market. Pricing: ~$89 per 2-week sensor + biweekly subscription model. Stelo carries Vertex AI / Gemini generative AI insight layer; per DEPLOY's biometric cluster framework, Stelo anchors the glucose-biometric cell + medical-sensor-with-AI-insight bridge cell.
Is Stelo FDA-cleared?
Yes, via FDA De Novo pathway March 2024: the first OTC CGM clearance for non-diabetic consumers. The De Novo pathway means FDA established a new regulatory category for OTC consumer CGM; cleared scope is general-wellness glucose monitoring for non-diabetics. Specifically NOT cleared for diabetes diagnosis or treatment decisions; those continue to require Dexcom G6 + G7 prescription-only medical-device CGM lines. Per DEPLOY's framework, the cleared scope is the verification anchor; marketing scope should not extend beyond OTC general-wellness indication.
How much does Stelo cost?
~$89 per 2-week sensor + biweekly subscription model. Stelo ships in 2-week sensor packs; biweekly subscription enables continuous coverage. The consumable-sensor business model is structurally distinct from other biometric cohort hardware: most biometric wearables operate one-time hardware purchase + optional subscription (Fitbit + Pixel Watch); Whoop subscription-only; Oura purchase + required membership. Stelo's biweekly-sensor structure reflects the medical-sensor heritage.
Stelo vs Abbott Lingo: what's the difference?
Same sensor modality (continuous glucose monitoring for consumers); different AI substance per Agent A Wave 3 gradient documentation. Stelo: genuine generative AI substance (Vertex AI / Gemini integration; LLM-based insight generation). Abbott Lingo: adaptive algorithmic AI substance (rule-based + pattern matching; not LLM-generative). Per DEPLOY's biometric cluster framework, the AI-substance distinction determines biometric cohort inclusion: Stelo passes the biometric-primary + AI-augmented boundary test via genuine generative substance; Lingo sits at the AI-substance gradient that makes biometric cluster inclusion cap-flag tier.
Can non-diabetics use Stelo?
Yes, that is exactly Stelo's cleared indication. Stelo is the first FDA-cleared OTC CGM for non-diabetic consumers (March 2024 De Novo). Cleared scope is general-wellness glucose monitoring for non-diabetics; consumers can purchase Stelo without prescription. The companion app surfaces glucose data + Vertex AI / Gemini generative AI insights. Per cap-flag discipline, Stelo is specifically NOT cleared for diabetes diagnosis or treatment; diabetic patients should use Dexcom G6 + G7 prescription-only medical-device CGM lines.
Why is Stelo in the biometric cluster instead of the medical device tier?
Per DEPLOY's biometric cluster framework, Stelo passes the biometric-primary + AI-augmented boundary test via genuine generative AI substance (Vertex AI / Gemini integration). The framework's boundary test asks: would the device exist without the AI layer? For Stelo: yes-but-degraded; the glucose sensor would still produce data, but the AI-insight layer adds the consumer-wellness interpretation that makes the OTC indication useful. Per Agent A Wave 2 + Wave 3 foundational, Stelo's bridge cell role (medical-sensor heritage + consumer-wellness FDA posture + AI-insight differentiation) puts it in the biometric cluster rather than the medical-device CGM tier (Dexcom G6 + G7).
Dexcom Stelo verified at glucose-biometric cell + medical-sensor-with-AI-insight bridge cell anchor in biometric cohort. First OTC CGM for non-diabetic consumers; FDA De Novo March 2024. Genuine generative AI substance via Vertex AI / Gemini integration (distinct from Abbott Lingo adaptive algorithmic AI per Agent A Wave 3 gradient). ~$89/2-week sensor + biweekly subscription consumable-sensor model. Cleared scope: OTC general-wellness for non-diabetics; marketing scope must not extend into diabetes management per cap-flag discipline. How DEPLOY verifies →
Continue reading
The biometric cluster
Biometric-primary + AI-augmented cohort framework; FDA-clearance gradient; cell-anchor role for medical-sensor-with-AI-insight bridge.
Read article →
What is Oura?
Study-first archetype; general-wellness FDA posture; cohort positioning across biometric subscription-model spectrum.
Read article →
What is Apple Watch?
Substantial-cleared archetype + cohort canonical reference; cardiac-monitoring biometric cohort vs glucose-biometric cell distinction.
Read article →
What is an AI wearable?
Adjacent AI wearables cohort; AI-substance spectrum framework parallels biometric AI-insight gradient distinctions.
Read article →
Compare alternatives
Dexcom registry entityStelo registry modelBiometric clusterVerified-vs-claimed framework
More in biometric wearables